BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Apollo Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Apollo Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06846554-540@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:APL-9796: Phase 2 readout est. (NCT06846554)
DESCRIPTION:APL-9796\, phase 2\, Pulmonary Arterial Hypertension.\nStudy: A
  Trial of "APL-9796'' in Adults With Pulmonary Hypertension\nEstimated pri
 mary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/apl-9796#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06846554
URL:https://assetmemo.bio/drug/apl-9796#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599813-1343@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:camoteskimab: Phase 2 readout est. (NCT07599813)
DESCRIPTION:camoteskimab\, phase 2\, Atopic Dermatitis.\nStudy: A Phase 2b 
 Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Ato
 pic Dermatitis\nEstimated primary completion: 31 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/camoteskimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07599813
URL:https://assetmemo.bio/drug/camoteskimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
